top of page
Longevity Industry 2.0 ra.png


DeepTech Engineering the Accelerated Trajectory of Human Longevity: The Blueprint and Pathway from Longevity Industry 1.0 to 2.0

Знімок екрана 2021-03-14 о 12.58.21.png

In 2020’s “Longevity Industry 1.0 - Defining the Biggest and Most Complex Industry in Human History”, we distilled the complex assembly of deep market intelligence and industry knowledge that Deep Knowledge Group has developed over the previous 5 years into a full-scope understanding of the global Longevity Industry, showing the public exactly how the international consortium of commercial and non-profit entities managed to define the overwhelmingly complex and multidimensional Longevity Industry for the first time, and how they created tangible framework for its systematization and forecasting.

Знімок екрана 2021-03-31 о 18.59.22.png

In reality, Longevity is the deepest of all DeepTech sectors, and occupies the very forefront of advanced biomedicine, sitting at the intersection of many domains of DeepTech and Frontier Technologies. The industry’s intersection with, and reliance upon, advanced technologies does not, however, exclude or preclude the fact that it is also deeply interconnected with specific behavioural and lifestyle interventions. What it does mean, however, is that the scope and sophistication of technology-based tools and methods of optimizing day-to-day Healthy Longevity are large, rapidly increasing, and much broader (and deeper) than many people may realize, extending far beyond simplistic approaches involving diet, exercise and supplements, encompassing DeepTech products and services that are becoming increasingly available to the consumer.


Whereas Longevity Industry 1.0 charted the inception and rise of the industry up to 2020, and provided the methodology and framework for defining and analyzing the industry, its sequel, ‘Longevity Industry 2.0: DeepTech Engineering the Accelerated Trajectory of Human Longevity - The Blueprint and Pathway from Longevity Industry 1.0 to 2.0’, outlines Deep Knowledge Group’s recent work towards formulating the pathway to Longevity Industry 2.0, and presents the framework for safeguarding the sector’s current upward trajectory and ensuring its optimized, sustainable growth towards its next stage and the realization of its practical benefits for humanity by the year 2030. The book outlines several issues (and proposed solutions) that we believe constitute the foremost bottlenecks and risks to a continuing, positive trajectory of development in Longevity science, policy, industry, finance and investment, and present a preliminary preview of the frameworks we are developing to help strategic decision makers, industry participants and the general public take greater control over the actual, real-world development of both the Longevity Industry and Healthy Human Longevity.


Meanwhile, the next book in the series, ‘Longevity Industry 3.0: Stable Acceleration of Longevity Industrialization to Achieve its Practical Humanitarian Impact by the Year 2027’, will present the framework and toolsets required to maximize the positive societal benefits and neutralize the potentially detrimental consequences of Longevity, and how to accelerate its major practical impacts (including economic growth and stabilization and additional socially-inclusive HALE and QALY-years for humanity ahead of standard timelines - not in 10 years, but in 6.

2010-2023: Evolution of the Longevity

Industry from Zero to 1.0

  • The Industrialization of Longevity

  • The Current State of Longevity Science, Business, Finance, and Practical Applications

  • Longevity Becomes National Priority Item for the Strategic Agenda of Progressive Governments

  • Transforming the Challenge and Deficit of Aging into the Opportunity and Asset of Longevity

  • Defining and De-Risking: Hype vs. Reality

2023-2027: DeepTech Engineering The Accelerated Trajectory of Human Longevity - The Blueprint and Pathway from 1.0 to 2.0

  • Global Industrialization of Longevity to Scale

  • The Evolution from Longevity Start-ups to Multi-Trillion Dollar Longevity Corporations

  • How AI-Driven Preventive Medicine will Disrupt BioTech and Healthcare Industries 

  • Novel Financial Instruments and InvestTech Solutions

  • The Rise of Progressive Longevity MegaHubs

PART I. The Evolution from 1.0 (Defining the Industry) to 2.0 (Applying the Framework for Industry Harmonization and Investment De-Risking)
Знімок екрана 2021-03-14 о 13.29.17.png
  • DeepTech Engineering the Practical Pathway From 1.0 to 2.0

  • Applying Deep Knowledge Group’s Longevity Industry Framework

  • Longevity Industry and the Path to the Fifth Industrial Revolution

  • Analytics to Engineer the DeepTech Trajectory of Longevity 2.0: The Evolution of Deep Knowledge Group’s Longevity Analytics

  • Achieving Tangible Results in Practical Human Longevity by 2030

PART II - The Business of Longevity 2023-2025
  • Global Longevity Industry Overview 2024

  • Longevity Market Maturation: Top Longevity Deals, Investments, IPOs and Industry Events 2020-2022

PART III - Longevity Policy & Governance: Rise of Longevity Technocracy
image (1).png
  • Longevity Will Define & Decide the Fate of Nations in Next 10 Years

  • Benchmarking Progressiveness of National, Regional and Municipal Longevity Industrial Strategies and National Development Plans

  • The Rise of Longevity Valley: Analysis of Most Ideal Regions to Become the First Fully Integrated Longevity Industry Hub

  • Longevity Governance Big Data Analytics Dashboard - Monitoring, SWOT Analysis and Practical Recommendation System

  • Ethics, Policy and Societal Pros and Cons: How Potential Negative Outcomes of Optimized Global Longevity Can be Neutralized

PART IV  - Longevity Financial Industry: Past, Present and Future
Знімок екрана 2021-03-14 о 13.29.25.png
  • Longevity Financial Industry Big Data Analytics Dashboard  

  • Benchmarking: Traditional, Modern and Progressive Approaches

  • Financial Futurism - Engineered Solutions to the Big Liquidity Gap: Stock Exchange, Investment Bank, Index Fund & Financial Instruments

PART V - The Science of Longevity: 2023 - 2025
Знімок екрана 2021-03-14 о 13.29.27.png
  • Longevity Science (R&D Landscape Overview) 2023

  • The Current State of Longevity Clinical Trials

  • The Future of Geroscience and Longevity R&D: Mice vs. Men, and the Paradigm Shift in Scientific Community Mindset toward Practical

PART VI - Longevity Medicine and Technology: Engineering Market-Ready Pathways for Practical Human Longevity by the Year 2030
Знімок екрана 2021-03-14 о 13.29.34.png
  • The Past, Present & Future of Practical Healthy Human Longevity

  • Biomarkers of Human Longevity: Market-Ready Solutions for………Companies, Investors, and National and Municipal Governments

  • Mice vs. Men: Integral Platforms for Safe Human Experimentation and Validation for Tangible Investment Decision Making & De-Risking

PART VII - Technologizing Human Performance: Pathway from Human 1.0 to Human 2.0
Знімок екрана 2021-03-14 о 13.29.37.png

Technologizing Human Performance:
The Pathway from Human 1.0 to Human 2.0

  • Convergences Between Longevity and Performance Enhancement

  • NeuroTech Special Case Study: Optimizing Cognitive Performance

  • SpaceTech Special Case Study: The Pathway from Mice on Earth to Men on Mars

  • AgeTech for All: Market Ready Approaches for Optimizing Non-Biomedical Aspects of Human Capacity and Performance

  • The Inevitable Intersection Between Human Health and Performance

PART VII - Ethics & Society: Optimizing the Impact of Longevity on Global Humanity
Знімок екрана 2021-03-14 о 13.29.40.png
  • The Ethical and Societal Pros and Cons of Longevity

  • Best and Worst Case Outcomes of the  Industrialization

  • Neutralizing Potential Negative Outcomes of Longevity

  • The Framework for Optimizing Positive Outcomes & Neutralizing Negative Consequences of Global Longevity Industrialization

  • Social Psychology as the Major Roadblock or Accelerating Factor Impacting the Societal and Ethical Outcomes of Longevity Industry

About the Author

Dmitry Kaminskiy is an innovative entrepreneur, investor, author and philanthropist dedicated to impact investment and ethical business, with a focus on engineering the accelerated trajectory of progressive technological development for the benefit of humanity.


Mr. Kaminskiy is a co-founder and managing partner of Deep Knowledge Group - a consortium of commercial and non-profit organizations active on many fronts in the realm of DeepTech and Frontier Technologies (AI, Longevity, Precision Medicine, FinTech, GovTech, InvestTech), ranging from scientific research to investment, entrepreneurship, analytics, policy and philanthropy.


  • He leads the activities of the consortium’s venture arms - Deep Knowledge Ventures, an investment fund focused on DeepTech and advanced science projects, and Longevity.Capital, which prioritizes the convergence of Longevity and Artificial Intelligence, areas in which it has unparalleled investment   and  exit  strategies.

  • He is a frequent speaker on the topics of AI and Longevity, including conferences organized in London by The Economist “Aging Societies and The Business of Longevity”, Financial Times “Smart Machines vs Smart People”, at the Future Finance Forum in Seoul “AI in Finance”, “Precision Medicine World Conference" in Silicon Valley, as well as several others at Oxford and Cambridge Universities. 

Mr. Kaminskiy serves as managing trustee of Biogerontology Research Foundation, the UK’s oldest Longevity focused charity.

bottom of page